Announcement

Acuitas Therapeutics wins Global Impact Award for LNPs in COVID vaccines

Acuitas Therapeutics, the Vancouver, BC-based biotech company co-founded by NMIN research leader Dr. Pieter Cullis, has been granted a Global Impact Award by Life Sciences British Columbia, in recognition of the company’s “extraordinary leadership and efforts they made in the development of COVID-19 vaccines.” Acuitas partnered with Pfizer and BioNTech… Read More »Acuitas Therapeutics wins Global Impact Award for LNPs in COVID vaccines

LNPs & mRNA vaccines: Dr. Pieter Cullis in Nature Reviews Materials

“There is no time like the present to try to achieve impossible dreams” The contributions of NMIN Research Leader Dr. Pieter Cullis toward enabling effective mRNA vaccines, most notably against COVID-19, continue to garner high-profile recognition. Most recently, Dr. Cullis was featured on CBC’s Quirks & Quarks; his role was… Read More »LNPs & mRNA vaccines: Dr. Pieter Cullis in Nature Reviews Materials

NMIN supports NanoCanada’s Canadian Nanomedicine Cluster initiative

NMIN is collaborating with its partner organization NanoCanada to build a Canadian Nanomedicine Cluster that will offer a hub for collaboration and partnerships, provide a database of expertise and capabilities, and showcase Canada’s leadership on the global stage. As part of this collaboration, NMIN Executive Director Dr. Diana Royce has… Read More »NMIN supports NanoCanada’s Canadian Nanomedicine Cluster initiative

NMIN names new Scientific Director & CEO Dr. Christine Allen

The NanoMedicines Innovation Network (NMIN), a national research network funded by the Government of Canada, has appointed Dr. Christine Allen Scientific Director & CEO, effective 1 July 2021. Dr. Allen is Associate Vice-President and Vice-Provost, Strategic Initiatives, and Professor in the Leslie Dan Faculty of Pharmacy, at the University of… Read More »NMIN names new Scientific Director & CEO Dr. Christine Allen

Recognition grows for role of LNPs and Canadian biotech in COVID-19 mRNA-based vaccines

Since news of the Pfizer-BioNTech COVID-19 vaccine first broke in November 2020, growing recognition has been given to the Canadian nanomedicine-based component underlying the vaccine’s effectiveness: the lipid nanoparticle (LNP) delivery system that originated from basic research by NMIN Scientific Director Dr. Pieter Cullis that started over 40 years ago… Read More »Recognition grows for role of LNPs and Canadian biotech in COVID-19 mRNA-based vaccines

NMIN researcher’s company develops new DNA-based COVID-19 vaccine

Edmonton-based company Entos Pharmaceuticals has developed a new DNA-based vaccine for COVID-19 that is expected to enter Phase 1 clinical trials soon. NMIN researcher Dr. John Lewis, associate professor of oncology at the University of Alberta, is CEO of Entos. At the outset of the pandemic, the company repurposed its… Read More »NMIN researcher’s company develops new DNA-based COVID-19 vaccine